Norethindrone Acetate Patch
Description: Norethindrone acetate transdermal delivery system (patch).
Product Details
Duration: One week
Regimen:
Active Pharmaceutical Ingredient (API):
Status Details
Status Details: - Phase III completed in 2012. NDA filed with US FDA in 2013. Received complete response letter from FDA in late 2013 (product was not approved).
- Phase III completed in 2012. NDA filed with US FDA in 2013. Received complete response letter from FDA in late 2013 (product was not approved).
Additional Information
Footnotes: - Phase III study conducted by Watson Pharmaceuticals, which is now Actavis. After Actavis bought out Allergan, Actavis began using the Allergan name.
- Phase III study conducted by Watson Pharmaceuticals, which is now Actavis. After Actavis bought out Allergan, Actavis began using the Allergan name.